From ASPHALION, we would like to inform you of the opening of the call:
- HORIZON-HLTH-2022-DISEASE-06-02-two-stage: “Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs”
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”.
Immunotherapy is defined as a treatment able to stimulate or restore the ability of the immune (defence) system to fight infection, disease or disorder. It has proved to be a valuable medical treatment notably when preventive interventions are not available. Passive and active immunotherapies (such as antibody-based, RNA-based and cell-based therapies, respectively) are covered by this topic, which is aiming at the pre-clinical to first-in human development of next generation immunotherapies for unmet needs.
ASPHALION, as SME company, is actively involved in more than 15 EU granted projects as regulatory expert partners.
Whether you are planning to apply and you would like to add a regulatory partner to the project, or if you are interested in knowing more about ASPHALION and our European granted projects expertise, do not hesitate to contact us at: horizon@asphalion.com
